Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition and application thereof

A technology of nitrophthalazinone and inhibitors, which is applied in the field of medicinal chemistry and can solve problems such as unsatisfactory selectivity, drug resistance, and multiple side effects

Inactive Publication Date: 2019-01-29
NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] It is currently known that the selectivity of BTK inhibitors is not ideal. In addition to inhibiting BTK, it also inhibits various other kinases (such as ETK, EGF, BLK, FGR, HCK, YES, BRK and JAK3, etc.), resulting in more side effects; at the same time , BTK binding site mutations often lead to drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition and application thereof
  • Taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition and application thereof
  • Taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Preparation of 8-nitro-2H-phthalazin-1-one

[0028]

[0029] Step 1: Weigh 3-nitro-1-dimethoxymethylbenzene (500mmol) into a reaction flask, add tetrahydrofuran (800ml) to dissolve, add s-BuLi (565mmol) under nitrogen protection at 60°C, and The reaction solution was stirred at -60 °C for 1 h.

[0030] Step 2: Weigh dry ice (50mmol) into a reaction flask, add tetrahydrofuran (200ml), add n-BuLi (5ml), stir for 2h under nitrogen protection, add the mixture of step 1, continue stirring for 30min, stop the reaction, add water 1000ml, adjust the pH to 2 with concentrated hydrochloric acid, separate the organic phase, extract the aqueous phase with ethyl acetate, combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, and recrystallize to obtain 3-nitro-2-dimethoxy methylbenzoic acid.

[0031] Step 3: Weigh the product obtained in Step 2 (400mmol), acetic acid (93mmol), and hydrazine (600mmol) into a reaction flask, add 300ml ...

Embodiment 2

[0033] Example 2 Preparation of (3,4-dihydroisoquinoline-2(1H)-formic acid tert-butyl ester-5-yl)-carbamic acid p-chlorobenzyl ester

[0034]

[0035] Weigh triphosgene (5mmol) into a reaction bottle, add 100ml of toluene, add dropwise 20ml of tetrahydrofuran solution dissolved with p-chlorophenol (5mmol) and pyridine (10ml) at 0°C, after the drop is completed, continue to react at room temperature for 8h, concentrate the reaction solution, added 40ml of dichloromethane, suspended to dryness, and obtained p-chlorobenzyl chloroformate, which was directly used in the next step.

[0036]Weigh 5-amino-3,4-dihydroisoquinoline-2(1H)-tert-butyl carboxylate (50mmol) and DIPEA (100mmol) into a reaction flask, add 300ml of dichloromethane, and slowly add it dropwise under stirring at room temperature p-chlorobenzyl chloroformate (51mmol), after dropping, continue to stir at room temperature for 1h, stop the reaction, concentrate the reaction mixture, add 70ml of ethyl acetate, wash w...

Embodiment 3

[0038] Example 3 (3,4-dihydroisoquinoline-2(1H)-tert-butyl formate-5-yl)-carbamic acid-4-[8-nitro-(2H)-phthalazin-1-one Preparation of base] benzyl ester

[0039]

[0040] Weigh 8-nitro-2H-phthalazin-1-one and (3,4-dihydroisoquinoline-2(1H)-formic acid tert-butyl ester-5-yl)-carbamic acid p-chlorobenzyl ester (195mmol ) into the reaction bottle, add DMF100ml, react overnight at 55°C, stop the reaction, add water 100ml, dichloromethane 200ml, extract, separate the organic phase, continue to extract the water phase with dichloromethane (3*50ml), combine the organic phase , dried over anhydrous sodium sulfate, and purified by column chromatography to obtain the title compound.

[0041] ESI–MS:[M+H] + m / z 572.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a taxol and novel nitrophthalazinone BTK inhibitor combined pharmaceutical composition, which consists of an active ingredient and pharmaceutically acceptable adjuvants, whereinthe active ingredient is composed of taxol and a BTK inhibitor shown as formula (I) (as shown in Description); and the mole ratio of the taxol to the BTK inhibitor shown as formula (I) in the activeingredient is at (0.14-0.20) to 1. The pharmaceutical composition can be used for preparing medicines for preventing and / or treating diseases related to Bruton's tyrosine kinase, with a good therapeutic effect.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, and relates to phthalazinone BTK inhibitors and applications thereof, in particular to phthalazinone BTK inhibitors, a preparation method thereof, a pharmaceutical composition containing the compound, and its application in the treatment of Bruton casein Use in amino acid kinase-associated diseases. Background technique [0002] Bruton's tyrosine kinase (BTK) is a member of the Tec family. It consists of a unique N-terminal domain, namely PH (pleckstrin homology) domain, TH (Tec homology) homology region, SH3 (Srchomology3) domain, SH2 (Src homology2) domain and catalytic domain, also known as SH1 / TK (Srchomologyl / Tyrosine kinase) domain or kinase domain composition (Akinleye et al: Ibrutiniband novel BTK inhibitors in clinical development. Journal of Hematology & Oncology 2013, 6: 59). During the normal development of B lymphocytes, the correct expression of different protein regions of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/502A61K31/337A61K31/454A61P35/00A61P35/02
CPCA61P35/00A61P35/02A61K31/337A61K31/454A61K31/502A61K2300/00
Inventor 郭程杰
Owner NANJING ADVANCED BIOLOGICAL MATERIALS & PROCESS EQUIP INST CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com